NCT06830863View on ClinicalTrials.gov

A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 25, 2025

Primary Completion Date

March 15, 2026

Study Completion Date

May 15, 2026

Conditions
EGFR Inhibitor-associated Rash
Interventions
DRUG

ATR04-484

ATR04-484 is a recombinant live biotherapeutic product (rLBP) containing the engineered S. epidermidis strain SE484 in an ointment formulation for topical use

DRUG

Vehicle

Topically applied vehicle.

Trial Locations (4)

10016

RECRUITING

NYU Langone, New York

22031

RECRUITING

Inova Schar Cancer, Fairfax

43230

RECRUITING

The Ohio State University, Gahanna

06510

RECRUITING

Yale University School of Medicine, New Haven

Sponsors

Lead Sponsor

Azitra Inc.
All Listed Sponsors
collaborator

Prosoft Clinical

OTHER

lead

Azitra Inc.

INDUSTRY

NCT06830863 - A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity | Biotech Hunter | Biotech Hunter